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Lopinavir–ritonavir in patients admitted to hospital with 
COVID-19 (RECOVERY): a randomised, controlled, open-label, 
platform trial
RECOVERY Collaborative Group*
Summary
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, 
preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether 
lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19.
Methods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with 
usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible 
and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus 
lopinavir–ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other 
RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple 
(unstratified) randomisation with allocation concealment. Randomisation to usual care was twice that of any of 
the active treatment groups (eg, 2:1 in favour of usual care if the patient was eligible for only one active group, 2:1:1 if 
the patient was eligible for two active groups). The primary outcome was 28-day all-cause mortality. Analyses were 
done on an intention-to-treat basis in all randomly assigned participants. The trial is registered with ISRCTN, 
50189673, and ClinicalTrials.gov, NCT04381936.
Findings Between March 19, 2020, and June 29, 2020, 1616 patients were randomly allocated to receive lopinavir–
ritonavir and 3424 patients to receive usual care. Overall, 374 (23%) patients allocated to lopinavir–ritonavir and 
767 (22%) patients allocated to usual care died within 28 days (rate ratio 1·03, 95% CI 0·91–1·17; p=0·60). Results 
were consistent across all prespecified subgroups of patients. We observed no significant difference in time until 
discharge alive from hospital (median 11 days [IQR 5 to >28] in both groups) or the proportion of patients discharged 
from hospital alive within 28 days (rate ratio 0·98, 95% CI 0·91–1·05; p=0·53). Among patients not on invasive 
mechanical ventilation at baseline, there was no significant difference in the proportion who met the composite 
endpoint of invasive mechanical ventilation or death (risk ratio 1·09, 95% CI 0·99–1·20; p=0·092).
Interpretation In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions 
in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. These 
findings do not support the use of lopinavir–ritonavir for treatment of patients admitted to hospital with COVID-19.
Funding Medical Research Council and National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), the cause of COVID-19, emerged in China 
in late 2019 from a zoonotic source. Most COVID-19 
infections are either asymptomatic or result in only mild 
disease.1 However, a proportion of infected individuals 
develop a respiratory illness that requires hospital care, 
which can progress to critical illness with hypoxaemic 
respiratory failure that requires prolonged ventilatory 
support. Among patients with COVID-19 admitted to 
UK hospitals, the case fatality rate is over 26%, and is in 
excess of 37% in patients who require invasive mechanical 
ventilation.2
The drug combination lopinavir–ritonavir has been sug-
gested as an antiviral treatment for COVID-19.3 Lopinavir 
is a HIV-1 protease inhibitor, which is combined with 
ritonavir to increase its plasma half-life. Lopinavir is also 
an inhibitor of the severe acute respiratory syndrome 
coronavirus (SARS-CoV) main protease, which is critical 
for replication and appears to be highly conserved in 
SARS-CoV-2.4,5 Lopinavir has in vitro inhibitory activity 
against SARS-CoV, SARS-CoV-2, and Middle East res-
piratory syndrome (MERS) coronavirus.6–9 In a marmoset 
model of MERS, lopinavir–ritonavir improved clinical, 
radiological, and pathological outcomes and reduced viral 
loads.10 A study of lopinavir–ritonavir in a ferret model of 
COVID-19 found reduced clinical symptoms in treated 
animals but no effect on virus titres.11
In patients with severe acute respiratory syndrome, a 
historically controlled study suggested that addition of 
lopinavir–ritonavir to ribavirin reduced the risk of 
adverse clinical outcomes and viral load.12 Although some 
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observational studies in patients with COVID-19 have 
reported that lopinavir–ritonavir is associated with a 
shorter duration of viral shedding13 and fever,14 other 
studies have reported no such effects.15,16 A previous ran-
domised trial of lopinavir–ritonavir among 199 patients 
admitted to hospital with COVID-19 showed no 
improvement in viral load, duration of hospital stay, or 
mortality.17 However, the trial was too small to rule 
out the possibility of clinically relevant benefits and 
commentators recommended larger randomised trials to 
confirm or refute the lack of effect.18 Here, we report the 
results of a randomised trial to assess whether lopinavir–
ritonavir improves clinical outcomes in patients admitted 
to hospital with COVID-19.
Methods
Study design and participants
The randomised evaluation of COVID-19 therapy 
(RECOVERY) trial is an investigator-initiated, indivi-
dually randomised, open-label, platform trial to evaluate 
the effects of potential treatments in patients admitted 
to hospital with COVID-19.19,20 The trial is underway at 
176 hospitals in the UK (appendix pp 2–20), supported 
by the National Institute for Health Research Clinical 
Research Network. The trial is coordinated by the 
Nuffield Department of Population Health at University 
of Oxford (Oxford, UK), the trial sponsor. The trial 
is done in accordance with the principles of the 
International Conference on Harmonisation–Good 
Clinical Practice guidelines and approved by the UK 
Medicines and Healthcare products Regulatory Agency 
and the Cambridge East Research Ethics Committee 
(20/EE/0101). The protocol, statistical analysis plan, and 
additional infor mation are available on the study 
website.
Although the lopinavir–ritonavir, dexamethasone, and 
hydroxychloroquine groups have now been stopped, 
the trial continues to study the effects of azithromycin, 
tocilizumab, convalescent plasma, and REGN-CoV2 
(a combination of two monoclonal antibodies directed 
against SARS-CoV-2 spike protein). Other treat ments 
might be studied in the future.
Patients admitted to hospital were eligible for the study 
if they had clinically suspected or laboratory confirmed 
SARS-CoV-2 infection and no medical history that might, 
in the opinion of the attending clinician, put the patient 
at substantial risk if they were to participate in the trial. 
Initially, recruitment was limited to patients who were 
aged at least 18 years, but from May 9, 2020, this age limit 
was removed. Patients with severe hepatic insufficiency 
or who were using medicinal products that are highly 
dependent on cytochrome P450 3A4 for clear ance and 
for whom elevated plasma concentrations would be 
associated with serious or life-threatening events (in line 
with the summary of product characteristics) were 
excluded from entry into the randomised comparison 
between lopinavir–ritonavir and usual care.21 Written 
informed consent was obtained from all patients, or their 
legal representative if they were too unwell or unable to 
provide consent.
Randomisation and masking
Baseline data were collected using a web-based case report 
form that included demographics, amount of respiratory 
support, major comorbidities, suitability of the study treat-
ments for a particular patient, and treatment availability at 
Research in context
Evidence before this study
We searched PubMed from inception up to July 23, 2020, 
for clinical trials published in English evaluating the effect of 
lopinavir–ritonavir among patients with laboratory-confirmed 
COVID-19 using the search terms (“COVID-19”[All Fields] OR 
“2019-nCoV”[All Fields]) OR “SARS-CoV-2”[All Fields]) AND 
(“lopinavir”[All Fields] OR “ritonavir”[All Fields]) (filters: Clinical 
Trial, Randomized Controlled Trial). We identified only one 
randomised clinical trial that compared lopinavir–ritonavir with 
usual care in patients with COVID-19. This trial assigned 
99 patients who had been admitted to hospital with COVID-19 to 
a lopinavir–ritonavir group (400 mg and 100 mg, respectively) 
and 100 patients to a standard-care group, and found no 
difference in viral clearance, time to clinical improvement, or 
28-day mortality between the two groups. However, the trial was 
underpowered to exclude clinically relevant treatment effects.
Added value of this study
To our knowledge, the randomised evaluation of COVID-19 
therapy (RECOVERY) trial is the first large-scale randomised 
clinical trial to report the effects of lopinavir–ritonavir in 
patients admitted to hospital with COVID-19. We found no 
significant difference between the lopinavir–ritonavir group 
and the usual care group in terms of 28-day mortality, the 
probability of discharge alive within 28 days, or, among 
patients who were not receiving invasive mechanical 
ventilation at randomisation, the probability of progressing to 
the composite outcome of invasive mechanical ventilation or 
death. We saw no evidence of benefit of lopinavir–ritonavir in 
any patient subgroup.
Implications of all the available evidence
Our finding of no clinical benefit from lopinavir–ritonavir 
treatment compared with standard care supports earlier 
findings from a smaller clinical trial. Many clinical care 
guidelines have recommended lopinavir–ritonavir for 
treatment of patients admitted to hospital with COVID-19. 
These guidelines should be updated.
For the protocol, statistical 
analysis plan, and additional 
information see 
www.recoverytrial.net
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the study site (appendix p 25). Eligible and consenting 
patients were assigned to either usual standard of care or 
usual standard of care plus lopinavir–ritonavir or one of 
the other available RECOVERY treatment groups using 
web-based simple (unstratified) randomisation with 
allocation conceal ed until after randomisation. Random-
isation to usual care was twice that of any of the active 
treatment groups the patient was eligible for (eg, 2:1 in 
favour of usual care if the patient was eligible for only 
one active group, 2:1:1 if the patient was eligible for two 
active groups). For some patients, lopinavir–ritonavir was 
unavailable at the hospital at the time of enrolment or was 
considered by the attending clinician to be either definitely 
indicated or definitely contraindicated. These patients 
were excluded from the randomised comparison between 
lopinavir–ritonavir and usual care and hence are not 
included in this report. Patients allocated to lopinavir–
ritonavir were to receive lopinavir 400 mg plus ritonavir 
100 mg by mouth every 12 h for 10 days or until discharge, 
if sooner. Allocated treatment was prescribed by the 
attending cli nician. Participants and local study staff 
were not masked to the allocated treatment. The trial 
steering committee, investigators, and all other individuals 
involved in the trial were masked to outcome data during 
the trial.
Procedures
A single online follow-up form was completed when 
participants were discharged alive from hospital, died, or 
at 28 days after randomisation, whichever occurred 
earliest (appendix pp 27–30). Information was recorded 
on adherence to allocated study treatment, receipt of 
other COVID-19 treatments, duration of admission, 
receipt of respiratory or renal support, and vital status 
(including cause of death). Additionally, routine health-
care and registry data were obtained including 
information on vital status (with date and cause of death), 
discharge from hospital, receipt of respiratory support, or 
renal replace ment therapy.
Outcomes
Outcomes were assessed at 28 days after randomisation, 
with further analyses specified at 6 months. The pri-
mary outcome was 28-day all-cause mortality. Secondary 
outcomes were time to discharge from hospital and, 
among patients not on invasive mechanical ventilation at 
randomisation, post-enrolment use of invasive mecha-
nical ventilation (including extracorporeal membrane 
oxygenation) or death. Prespecified subsidiary clinical 
outcomes were cause-specific mortality, use of haemo-
dialysis or haemofiltration, major cardiac arrhythmia 
(recorded in a subset), and receipt and duration of 
ventilation (for which full data are still being collected 
from relevant routine sources).
 Information on suspected serious adverse reactions 
was collected in an expedited fashion to comply with 
regulatory requirements.
Statistical analysis
An intention-to-treat comparison was made between 
patients randomly assigned to lopinavir–ritonavir and 
patients randomly assigned to usual care but for whom 
lopinavir–ritonavir was both available and suitable 
as a treatment. For the primary outcome of 28-day 
mortality, the log-rank observed minus expected 
statistic and its variance were used to both test the null 
hypothesis of equal survival curves (ie, the log-rank 
test) and to calculate the one-step estimate of the 
average mortality rate ratio and its 95% CI. We 
constructed Kaplan-Meier survival curves to display 
cumulative mortality over the 28-day period. We used 
the same method to analyse time to hospital discharge, 
with patients who died in hospital right-censored on 
day 29 (as for such patients it was known that they 
were not discharged alive within 28 days). Median 
time to dis charge was derived from Kaplan-Meier 
estimates. For the pre specified composite secondary 
outcome of invasive mechanical ventilation or death 
Figure 1: Trial profile
*Number recruited overall during the period that participants could be recruited into lopinavir–ritonavir 
comparison. †Some patients were included in both of the below groups. ‡A second randomisation to tocilizumab 
versus usual care in patients with hypoxia and C-reactive protein ≥75 mg/L was introduced in protocol version 4.0.
3424 allocated usual care alone
    5 of 3410 patients with 
completed follow-up at time 
of analysis received 
lopinavir–ritonavir
 
251 proceeded to second 
randomisation‡
 
7 withdrew consent 
7825 randomised between lopinavir−ritonavir 
and other RECOVERY groups
5040 randomised between lopinavir−ritonavir 
and usual care alone
2785 allocated to other active treatment
 1184 dexamethasone
 1009 hydroxychloroquine
 592 azithromycin
11 847 patients recruited*
 
4022 excluded†
 1276 lopinavir−ritonavir unavailable
 3063 lopinavir–ritonavir considered unsuitable
3424 included in 28-day intention-to- 
treat analysis
1616 allocated lopinavir−ritonavir
1394 of 1603 patients with 
completed follow-up at 
time of analysis received 
lopinavir–ritonavir
 
115 proceeded to second 
randomisation‡
4 withdrew consent
 
1616 included in 28-day intention-to- 
treat analysis
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within 28 days (among those not receiving invasive 
mechanical ventilation at randomisation), the precise 
date of invasive mecha nical ventilation was not 
available and so the risk ratio was estimated instead.
Prespecified analyses of the primary outcome were done 
separately in six subgroups defined by characteristics at 
the time of random assignment: age, sex, ethnicity, level 
of respiratory support, days since symptom onset, and 
predicted 28-day mortality risk (appendix p 23). Observed 
effects within subgroup categories were compared using a 
χ² test for heterogeneity or trend, in accordance with the 
prespecified analysis plan.
Estimates of rate ratios and risk ratios are shown 
with 95% CIs. All p values are two-sided and are shown 
without adjustment for multiple testing. The full data base 
is held by the study team that collected the data from study 
sites and did the analyses at the Nuffield Department of 
Population Health (University of Oxford, Oxford, UK).
As stated in the protocol, appropriate sample sizes 
could not be estimated when the trial was being 
planned since the numbers that could be enrolled are 
dependent on how large the epidemic becomes. 
However, our aim was to randomise several thousand 
patients (appendix p 22). The independent data moni-
toring committee reviewed unblinded analyses of the 
study data and any other information considered 
relevant at intervals of around 2 weeks. The committee 
was charged with determining if, in their view, the 
randomised comparisons in the study provided evidence 
on mortality that was strong enough (with a range of 
uncertainty around the results that was narrow enough) 
to affect national and global treatment strategies 
(appendix p 31). In such a circumstance, the committee 
would inform the chief investigators who would make 
the results available to the public and amend the trial 
accordingly.
On June 25, 2020, the independent data monitoring 
committee conducted a routine review of the data and 
recommended that the chief investigators review the 
unblinded data on the lopinavir–ritonavir comparison 
with usual care. The chief investigators and steering 
committee concluded that the data showed no beneficial 
effect of lopinavir–ritonavir in patients admitted to 
hospital with COVID-19. Therefore, enrolment of 
participants to the lopinavir–ritonavir group was closed 
on June 29, and the preliminary result for the primary 
outcome was made public. Investigators were advised 
that any patients currently taking lopinavir–ritonavir as 
part of the study should discontinue.
Analyses were done using Stata version 15.1 and 
R version 3.4 and validated using SAS version 4. The trial 
is registered with ISRCTN, 50189673, and ClinicalTrials.
gov, NCT04381936.
Lopinavir–ritonavir 
(n=1616)
Usual care 
(n=3424)
Age, years 66·0 (16·0) 66·4 (15·8)
<70* 920 (57%) 1910 (56%)
≥70 to <80 321 (20%) 706 (21%)
≥80 375 (23%) 808 (24%)
Sex
Men 973 (60%) 2104 (61%)
Women† 643 (40%) 1320 (39%)
Ethnicity
White 1240 (77%) 2541 (74%)
Black, Asian, and minority 
ethnic
250 (15%) 615 (18%)
Unknown 126 (8%) 268 (8%)
Number of days since 
symptom onset
8 (5–12) 8 (4–12)
Number of days since 
admission to hospital
2 (1–4) 2 (1–4)
Respiratory support received
No oxygen received 425 (26%) 896 (26%)
Oxygen only‡ 1131 (70%) 2384 (70%)
Invasive mechanical 
ventilation
60 (4%) 144 (4%)
Previous diseases
Diabetes 430 (27%) 958 (28%)
Heart disease 403 (25%) 908 (27%)
Chronic lung disease 386 (24%) 776 (23%)
Tuberculosis 4 (<1%) 12 (<1%)
HIV 3 (<1%) 3 (<1%)
Severe liver disease§ 0 0
Severe kidney impairment¶ 113 (7%) 263 (8%)
Any of the above 918 (57%) 1962 (57%)
Severe acute respiratory syndrome coronavirus 2 test result
Positive 1399 (87%) 3024 (88%)
Negative 207 (13%) 388 (11%)
Unknown 10 (1%) 12 (<1%)
Data are mean (SD), n (%), or median (IQR). *Includes two children (<18 years). 
†Includes six pregnant women. ‡Includes non-invasive ventilation. §Defined as 
requiring ongoing specialist care. ¶Defined as estimated glomerular filtration rate 
<30 mL/min per 1·73 m².
Table 1: Baseline characteristics
Figure 2: Effect of allocation to lopinavir–ritonavir on 28-day mortality
Number at risk
Active
Control
0
1616
3424
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1422
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2650
Time since randomisation (days)
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25
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100
M
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)
Lopinavir−ritonavir
Usual care
Rate ratio 1·03 (0·91–1·17)
Log-rank p=0·60
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. PWH and MJL had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between March 19, 2020, and June 29, 2020, 
7825 (66%) of 11 847 patients randomly assigned when 
the lopinavir–ritonavir group was open for enrolment 
were eligible to be randomly allocated to lopinavir–
ritonavir (lopinavir–ritonavir was available in the 
hospital and the attending clinician was of the opin-
ion that the patient had no known indication for 
or contraindication to lopinavir–ritonavir; figure 1; 
appendix p 33). 1616 patients were randomly allocated to 
lopinavir–ritonavir and 3424 were randomly allocated to 
usual care, with the remainder being randomly allocated 
to one of the other RECOVERY treatment groups. The 
mean age of study participants in this com parison was 
66·2 years (SD 15·9; table 1; appendix p 33). At 
randomisation, about a quarter of patients had no 
ventilatory support, most were receiving oxygen only, 
and a very small proportion were on inva sive mechanical 
ventilation (table 1).
Follow-up information was complete for 5018 (>99%) 
of 5040 patients (1606 [99%] of 1616 patients in the 
lopinavir–ritonavir group and 3412 [>99%] of 3424 patients 
in the usual care group). Among patients with a completed 
follow-up form, 1394 (87%) allocated to lopinavir–ritonavir 
received at least one dose (figure 1; appendix p 34). The 
median duration of treatment was 5 days (IQR 2–8). In the 
usual care group, five patients (<1%) received lopinavir–
ritonavir. Use of azithromycin or another macrolide as 
part of clinical care during follow-up was similar in both 
groups (374 [23%] patients in the lopinavir–ritonavir group 
vs 862 [25%] in the usual care group), as was use of 
dexamethasone (160 [10%] vs 355 [10%]; appendix p 34).
51 (3%) of 1616 patients in the lopinavir–ritonavir group 
and 128 (4%) of 3424 patients in the usual care group 
proceeded to second randomisation and were allocated to 
tocilizumab in accordance with protocol version 4.0 or 
later. 72 patients were additionally randomly assigned 
to convalescent plasma versus control (19 [1%] patients 
allocated to lopinavir–ritonavir vs 53 [2%] patients allocated 
to usual care) in accordance with protocol version 6.0. 
Among the 163 sites that randomly assigned at least one 
patient to the lopinavir–ritonavir comparison, the median 
number of patients randomised was 22 (IQR 11–42).
We observed no significant difference in the propor-
tion of patients who met the primary outcome of 
Figure 3: Effect of allocation to lopinavir–ritonavir on 28-day mortality by baseline characteristics
Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines 
through them correspond to the 95% CIs. The ethnicity and days since onset subgroups exclude those with missing data, but these patients are included in the overall 
summary diamond. The method used to calculate baseline predicted risk is described in the appendix (p 23). The χ² statistics correspond to tests for trend (or 
heterogeneity) in the log rate ratios across the levels of each subgroup. *Includes patients receiving non-invasive ventilation.
Age, years (χ21=0·0; p=0·96)
<70
≥70 to <80
≥80
Sex (χ21=1·4; p=0·24)
Men
Women
Ethnicity (χ21=0·3; p=0·57)
White
Black, Asian, and minority ethnic
Days since symptom onset (χ21=0·4; p=0·51)
≤7
>7
Respiratory support at randomisation (χ21=0·6; p=0·46)
No oxygen received
Oxygen only*
Invasive mechanical ventilation
Baseline risk (χ21=0·1; p=0·74)
<30%
≥30% to <45%
≥45%
All participants
Favours lopinavir−ritonavir Favours usual care
0·5 0·75 1·0 1·5 2·0
 112/920 (12%)
 103/321 (32%)
 159/375 (42%)
 255/973 (26%)
 119/643 (19%)
 311/1240 (25%)
 37/250 (15%)
 205/735 (28%)
 169/881 (19%)
 71/425 (17%)
 279/1131 (25%)
 24/60 (40%)
 147/1101 (13%)
 118/309 (38%)
 109/206 (53%)
 374/1616 (23%)
Lopinavir–ritonavir
 226/1910 (12%)
 212/706 (30%)
 329/808 (41%)
 508/2104 (24%)
 259/1320 (20%)
 634/2541 (25%)
 82/615 (13%)
 396/1527 (26%)
 365/1888 (19%)
 126/896 (14%)
 586/2384 (25%)
 55/144 (38%)
 266/2266 (12%)
 274/695 (39%)
 227/463 (49%)
 767/3424 (22%)
Usual care
1·03 (0·82–1·30)
1·07 (0·84–1·36)
1·04 (0·86–1·27)
1·10 (0·94–1·28)
0·94 (0·75–1·16)
1·00 (0·87–1·15)
1·13 (0·76–1·68)
1·08 (0·91–1·28)
0·99 (0·83–1·19)
1·21 (0·90–1·64)
1·00 (0·86–1·15)
1·11 (0·67–1·82)
1·15 (0·94–1·42)
0·94 (0·76–1·17)
1·11 (0·88–1·41)
1·03 (0·91–1·17); p=0·60
Rate ratio (95% CI)
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28-day mortality between the two randomised groups 
(374 [23%] patients in the lopinavir–ritonavir group vs 
767 [22%] patients in the usual care group; rate ratio 1·03, 
95% CI 0·91–1·17; p=0·60; figure 2). We observed similar 
results across all prespecified subgroups (figure 3). 
In a post-hoc exploratory analysis restricted to the 
4423 (88%) patients with a positive SARS-CoV-2 test result, 
the result was similar (rate ratio 1·05, 0·92–1·19; p=0·49).
Allocation to lopinavir–ritonavir was associated with a 
similar time until discharge alive from hospital as usual 
care (median 11 days [IQR 5 to >28] in both groups) and a 
similar probability of discharge alive from hospital 
within 28 days (rate ratio 0·98, 95% CI 0·91–1·05; 
p=0·53; table 2). Among individuals not on invasive 
mechanical ventilation at baseline, the number of 
patients who progressed to the prespecified composite 
secondary outcome of invasive mechanical ventilation or 
death among those allocated to lopinavir–ritonavir was 
similar to that among those allocated to usual care (risk 
ratio 1·09, 0·99–1·20; p=0·092; table 2).
We found no significant differences in cause-specific 
mortality (appendix p 35). Among those not on renal 
dialysis or haemofiltration at randomisation, the 
number of patients requiring this treatment within 
28 days was similar between the two groups (66 [4%] of 
1588 patients in the lopinavir–ritonavir group vs 140 [4%] 
of 3348 patients in the usual care group; risk ratio 0·99, 
95% CI 0·75–1·32; p=0·97). We observed no significant 
differences in the frequency of new cardiac arrhythmias 
(appendix p 36). There was one report of a serious 
adverse reaction thought to be related to lopinavir–
ritonavir, which was a case of elevated alanine amino-
transferase that did not meet standard criteria for 
drug-induced liver injury and from which the patient 
recovered after stopping treatment.
Discussion
The results of this large randomised trial indicate that 
lopinavir–ritonavir is not an effective treatment for 
patients admitted to hospital with COVID-19. The lower 
bound of the confidence limit for the primary outcome 
rules out any reasonable possibility of a meaningful 
mortality benefit. Additionally, allocation to lopinavir–
ritonavir was not associated with reductions in the 
duration of hospital stay or the risk of being ventilated or 
dying for those not on ventilation at baseline. These 
results were consistent across subgroups of age, sex, 
ethnicity, duration of symptoms before randomisation, 
amount of respiratory support at randomisation, and 
baseline predicted risk of death at randomisation.
It is unclear whether the dose of lopinavir–ritonavir 
we used achieved adequate SARS-CoV-2 inhibitory 
concentrations in the lungs.22 Data on the in vitro 50% 
maximum effective concentration (EC50) of lopinavir–
ritonavir against SARS-CoV-2 are limited and variable, 
having been variously reported as 3·6, 5·7, and 
9·6 μg/mL.23 Although the extensive protein binding of 
lopinavir (>95%) might result in unbound plasma drug 
concentrations below the highest reported EC50,22,24 the 
reported in vitro EC50 data have been generated in the 
presence of some serum protein and so do not represent 
a zero protein binding value. Additionally, concentrations 
of lopinavir in patients with COVID-19 have been 
reported to be substantially higher than in patients 
with HIV, perhaps due to inhibition of CYP3A4 meta-
bolism by inflammation.24–27 A pharmacokinetic analysis 
of a range of putative SARS-CoV-2 antiviral drugs has 
predicted that lopinavir–ritonavir at the doses we used 
would achieve lung concentrations above the EC90, albeit 
not across the entire dosing interval.23
Our trial, which focused on providing clear information 
on the effect of lopinavir–ritonavir on unambiguous 
clinical outcomes, including all-cause mortality, has 
several limitations. Since the safety profile of lopinavir–
ritonavir is well established, we did not collect detailed 
information on non-serious adverse reactions or reasons 
for stopping treatment. Neither did we collect infor-
mation on physiological, laboratory, or virological para-
meters, which have been studied previously.17 Finally, 
very few intubated patients with COVID-19 were enrolled 
in this study as there were difficulties in administering 
treatment to patients who could not swallow. Crushing 
lopinavir–ritonavir tablets for administration down a 
feeding tube results in unreliable bioavailability and 
potential tube blockage.28,29 Although a liquid formulation 
of lopinavir–ritonavir exists, it was unavailable for this 
study and, since the liquid formulation contains alcohol, 
is not compatible with the polyurethane feeding tubes 
that are commonly used in the UK.
The results from the RECOVERY trial show that 
lopinavir–ritonavir monotherapy is not an effective treat-
ment for patients admitted to hospital with COVID–19. 
Treatment of COVID-19 with lopinavir–ritonavir has been 
recommended as a first-line or second-line in many 
countries.3 Since our preliminary results were made public 
on June 29, 2020, WHO has halted the lopinavir–ritonavir 
Lopinavir–ritonavir 
(n=1616)
Usual care 
(n=3424)
RR (95% CI) p value
Primary outcome
28-day mortality 374 (23%) 767 (22%) 1·03 (0·91–1·17) 0·60
Secondary outcomes
Discharged from hospital 
within 28 days
1113 (69%) 2382 (70%) 0·98 (0·91–1·05) 0·53
Receipt of invasive mechanical 
ventilation or death*
449/1556 (29%) 871/3280 (27%) 1·09 (0·99–1·20) 0·092
Invasive mechanical 
ventilation
152/1556 (10%) 279/3280 (9%) 1·15 (0·95–1·39) 0·15
Death 350/1556 (22%) 712/3280 (22%) 1·04 (0·93–1·16) 0·54
Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality and hospital 
discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). 
*Analyses exclude those on invasive mechanical ventilation at randomisation.
Table 2: Effect of allocation to lopinavir–ritonavir on key study outcomes
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monotherapy and the lopinavir–ritonavir plus interferon 
beta combination groups of the SOLIDARITY trial because 
the interim results are in line with those presented here—
lopinavir–ritonavir does not improve clinical outcomes for 
patients admitted to hospital with COVID-19.30
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